Update on Prostate Cancer Vaccines

Overview

Journal Cancer J

Specialty Oncology

Date 2011 Sep 29

PMID 21952278

Citations 12

Authors

Charles G Drake

Affiliations

Soon will be listed here.

Abstract

The recent approval of Sipuleucel-T (Dendreon, Seattle, WA) from the Food and Drug Administration for the treatment of men with asymptomatic or minimally symptomatic castrate-resistant prostate cancer was a landmark in cancer immunotherapy, making this the first cancer "vaccine" approved for use in a treatment setting. This approval has led to renewed interest in cancer vaccines and to the recognition that prostate cancer represents an immunologically sensitive disease. At the current time, several vaccine approaches are under clinical investigation. These include viral vectors, antigen-loaded dendritic cells, and DNA vaccines. Each approach has its own set of advantages and disadvantages. This review will introduce the basic technology underlying these different vaccines and briefly discuss completed and ongoing clinical trials. As a great number of prostate cancer vaccines have been investigated in both preclinical and clinical settings, we will focus primarily on vaccines that are currently in clinical trials, as ascertained by a recent inquiry of the clinical trials database, www.clinicaltrials.gov.

Citing Articles

Therapeutic metastatic prostate cancer vaccines: lessons learnt from urologic oncology.

Lasek W, Zapala L Cent European J Urol. 2021; 74(3):300-307.

PMID: 34729217 PMC: 8552937. DOI: 10.5173/ceju.2021.0094.

Standing Variations Modeling Captures Inter-Individual Heterogeneity in a Deterministic Model of Prostate Cancer Response to Combination Therapy.

Jain H, Sorribes I, Handelman S, Barnaby J, Jackson T Cancers (Basel). 2021; 13(8).

PMID: 33919753 PMC: 8070719. DOI: 10.3390/cancers13081872.

Dendritic cell vaccine immunotherapy; the beginning of the end of cancer and COVID-19. A hypothesis.

Saadeldin M, Abdel-Aziz A, Abdellatif A Med Hypotheses. 2020; 146:110365.

PMID: 33221134 PMC: 7836805. DOI: 10.1016/j.mehy.2020.110365.

Advances on immunotherapy in genitourinary and renal cell carcinoma.

Botta G, Granowicz E, Costantini C Transl Cancer Res. 2017; 6(1):17-29.

PMID: 28966917 PMC: 5617347. DOI: 10.21037/tcr.2017.02.09.

Personalized peptide vaccines and their relation to other therapies in urological cancer.

Kimura T, Egawa S, Uemura H Nat Rev Urol. 2017; 14(8):501-510.

PMID: 28561807 DOI: 10.1038/nrurol.2017.77.

References

Amato R, Drury N, Naylor S, Jac J, Saxena S, Cao A . Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. J Immunother. 2008; 31(6):577-85. DOI: 10.1097/CJI.0b013e31817deafd. View

Fong L, Ruegg C, Brockstedt D, Engleman E, Laus R . Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol. 1997; 159(7):3113-7. View

Ulmer J, Deck R, DeWitt C, Friedman A, Donnelly J, Liu M . Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine. 1994; 12(16):1541-4. DOI: 10.1016/0264-410x(94)90081-7. View

Williams S, Singh P, Isaacs J, Denmeade S . Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer?. Prostate. 2006; 67(3):312-29. DOI: 10.1002/pros.20531. View

Lubaroff D, Konety B, Link B, Gerstbrein J, Madsen T, Shannon M . Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res. 2009; 15(23):7375-80. PMC: 2787649. DOI: 10.1158/1078-0432.CCR-09-1910. View

Mercader M, Bodner B, Moser M, Kwon P, Park E, Manecke R . T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001; 98(25):14565-70. PMC: 64722. DOI: 10.1073/pnas.251140998. View

Abern M, Kaufman H, Latchamsetty K . An update on TroVax for the treatment of progressive castration-resistant prostate cancer. Onco Targets Ther. 2011; 4:33-41. PMC: 3116792. DOI: 10.2147/OTT.S14271. View

Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-22. DOI: 10.1056/NEJMoa1001294. View

Simons J, Sacks N . Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol. 2006; 24(5):419-24. DOI: 10.1016/j.urolonc.2005.08.021. View

10.

Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K . Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993; 90(8):3539-43. PMC: 46336. DOI: 10.1073/pnas.90.8.3539. View

11.

Aragon-Ching J, Williams K, Gulley J . Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007; 12:4957-71. DOI: 10.2741/2441. View

12.

Small E, Schellhammer P, Higano C, Redfern C, Nemunaitis J, Valone F . Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24(19):3089-94. DOI: 10.1200/JCO.2005.04.5252. View

13.

Burch P, Breen J, Buckner J, Gastineau D, Kaur J, Laus R . Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res. 2000; 6(6):2175-82. View

14.

Southall P, Boxer G, Bagshawe K, Hole N, Bromley M, Stern P . Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990; 61(1):89-95. PMC: 1971328. DOI: 10.1038/bjc.1990.20. View

15.

Hodi F, ODay S, Mcdermott D, Weber R, Sosman J, Haanen J . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363(8):711-23. PMC: 3549297. DOI: 10.1056/NEJMoa1003466. View

16.

Lee S, Croft M . 4-1BB as a therapeutic target for human disease. Adv Exp Med Biol. 2009; 647:120-9. DOI: 10.1007/978-0-387-89520-8_8. View

17.

Kaufman H, Wang W, Manola J, DiPaola R, Ko Y, Sweeney C . Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2004; 22(11):2122-32. DOI: 10.1200/JCO.2004.08.083. View

18.

Amato R, Hawkins R, Kaufman H, Thompson J, Tomczak P, Szczylik C . Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010; 16(22):5539-47. DOI: 10.1158/1078-0432.CCR-10-2082. View

19.

Finke L, Wentworth K, Blumenstein B, Rudolph N, Levitsky H, Hoos A . Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Vaccine. 2007; 25 Suppl 2:B97-B109. DOI: 10.1016/j.vaccine.2007.06.067. View

20.

Siemens D, Elzey B, Lubaroff D, Bohlken C, Jensen R, Swanson A . Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol. 2001; 166(2):731-5. DOI: 10.4049/jimmunol.166.2.731. View